Literature DB >> 9622663

NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants.

K Hayakawa1, T Itoh, H Niwa, T Mutoh, G Sobue.   

Abstract

The simultaneous administration of nerve growth factor (NGF) has been found to prevent experimental neuropathies induced by anti-cancer drugs such as cisplatin, vincristine and taxol. However, it is clinically important to know whether NGF is beneficial once the neuropathy is already manifest. We established a bioassay system to examine the preventive effects of NGF in various treatment schedules. NGF significantly prevented the inhibition of neurite outgrowth by vincristine and taxol regardless of treatment schedules. The pre-treatment and co-treatment schedules were effective against cisplatin, but the post-treatment schedule was not. With regard to the neurite and nerve cell population densities, only the cisplatin group treated with NGF showed lower values than the control. These results indicate that NGF-treatment is effective for the toxic sympathetic nerve injury induced by vincristine and taxol regardless of the treatment schedule, but is not protective against cisplatin-induced nerve cell injury. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622663     DOI: 10.1016/s0006-8993(98)00305-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Neurologic Complications of Cancer Therapy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

2.  Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Haijun Zhang; Larry C Driver; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  J Pain       Date:  2011-06-24       Impact factor: 5.820

3.  Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.

Authors:  Óscar Arrieta; N Hernández-Pedro; M C Fernández-González-Aragón; D Saavedra-Pérez; A D Campos-Parra; M Á Ríos-Trejo; T Cerón-Lizárraga; L Martínez-Barrera; B Pineda; G Ordóñez; A Ortiz-Plata; V Granados-Soto; J Sotelo
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

4.  A novel system to accelerate the progression of nerve degeneration in transgenic mouse models of neuropathies.

Authors:  Osefame Ewaleifoh; Minh Trinh; John W Griffin; Thien Nguyen
Journal:  Exp Neurol       Date:  2012-06-09       Impact factor: 5.330

5.  Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes.

Authors:  T Natsume; T Nakamura; Y Koh; M Kobayashi; N Saijo; K Nishio
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 6.  Peripheral neuropathy and cancer.

Authors:  Arthur D Forman
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

7.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

8.  Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study.

Authors:  Hiroi Kaku; Seisuke Kumagai; Hiroki Onoue; Anna Takada; Tadahiro Shoji; Fumiharu Miura; Akira Yoshizaki; Shinya Sato; Junzo Kigawa; Tsutomu Arai; Shinpei Tsunoda; Eiichiro Tominaga; Daisuke Aoki; Toru Sugiyama
Journal:  Exp Ther Med       Date:  2011-10-24       Impact factor: 2.447

9.  Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants.

Authors:  Sarah E James; Hubert Burden; Russell Burgess; Youmei Xie; Tao Yang; Stephen M Massa; Frank M Longo; Qun Lu
Journal:  Neurotoxicology       Date:  2008-04-26       Impact factor: 4.294

10.  A quantitative bioassay for nerve growth factor, using PC12 clones expressing different levels of trkA receptors.

Authors:  Itzhak Katzir; Jashovam Shani; Keren Regev; Dalia Shabashov; Philip Lazarovici
Journal:  J Mol Neurosci       Date:  2002-06       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.